Company intelligence / Profile preview

Sun Pharma

Mumbai, Maharashtra, Indiasunpharma.com ↗

Ownership: Public · SUNPHARMA
Employees: ~41000
Development stage: Other

Overview

Sun Pharma has a robust global commercial presence with over $5.4 billion in annual revenue. Its specialty pipeline includes ILUMYA™ for moderate-to-severe plaque psoriasis and WINLEVI® for acne vulgaris. The company also markets Cequa for dry eye disease and Odomzo for basal cell carcinoma in the US. It maintains one of the world’s largest portfolios of generic drugs.

Therapeutic areas: PsychiatryDermatologyOphthalmologyOncologyCardiovascular
Modalities: Small moleculeBiologicMonoclonal antibodyPeptides
Industry: Biotech

Drug pipeline

15 assets

hydrocodone

Approved

14 more assets in the full pipeline.

Request access →

Partnerships

Merck & Co.: Licensing agreement for tildrakizumabChina Medical System Holdings

Beyond the preview

Go deeper on Sun Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sun Pharma.

Explore the full profile